Download presentation
Presentation is loading. Please wait.
Published byBrittany May Modified over 8 years ago
1
Office of In Vitro Diagnostic Device Evaluation and Safety Donald St.Pierre Deputy Director for New Device Evaluation RAPS 2003 Annual Conf. 10/22/03
2
OIVD Current Issues/Hot Topics CLIA Activities Premarket Activities Postmarket Activities
3
I.CLIA Status quo, but DHHS looking into delegation of authority
4
II. Premarket Activities Replacement Reagent Update & remove need for Add-to file Bundling Continuing smoothly Note: class I + class II = class II Not Bundling, but processing change e.g., HBV, PSA Expedited – Denovo & FDA Identified
5
Premarket Activities (con’t) Process in reverse Typical – application, then guidance Atypical – guidance, then application Multiplex (Microarray) Rapamycin BiMo Guidance Refocus efforts Informed consent/patient samples New 510(k) Review Models Too early to comment
6
III.Postmarket Activities Symbols Okay in 510(k)s – if no impact on SE decision Not okay in PMAs yet, but not taking action Electronic Labeling Okay for IVDs? If so, then good If not, then we’ll let you know so you can fight
7
Monitor the OIVD webpage for the latest on IVDs www.fda.gov/cdrh/oivd www.fda.gov/cdrh/oivd
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.